DE69019388D1 - Verwendung von N-Methyl-Sphingosin als Zell-Wachstums-Inhibitor. - Google Patents

Verwendung von N-Methyl-Sphingosin als Zell-Wachstums-Inhibitor.

Info

Publication number
DE69019388D1
DE69019388D1 DE69019388T DE69019388T DE69019388D1 DE 69019388 D1 DE69019388 D1 DE 69019388D1 DE 69019388 T DE69019388 T DE 69019388T DE 69019388 T DE69019388 T DE 69019388T DE 69019388 D1 DE69019388 D1 DE 69019388D1
Authority
DE
Germany
Prior art keywords
sphingosine
methyl
pharmaceutically acceptable
prepared
cell growth
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69019388T
Other languages
English (en)
Other versions
DE69019388T2 (de
Inventor
Yasuyuki Igarashi
Tatsushi Toyokuni
Sen-Itiroh Hakomori
Efraim Racker
Shuji Fujita
Mamoru Sugimoto
Masayoshi Ito
Yoshiyasu Shitori
Tomoya Ogawa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
KANTO ISHI PHARMA CO Ltd
Mect Corp
Cornell Research Foundation Inc
Biomembrane Institute
Original Assignee
KANTO ISHI PHARMA CO Ltd
Mect Corp
Cornell Research Foundation Inc
Biomembrane Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by KANTO ISHI PHARMA CO Ltd, Mect Corp, Cornell Research Foundation Inc, Biomembrane Institute filed Critical KANTO ISHI PHARMA CO Ltd
Application granted granted Critical
Publication of DE69019388D1 publication Critical patent/DE69019388D1/de
Publication of DE69019388T2 publication Critical patent/DE69019388T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69019388T 1989-02-03 1990-02-02 Verwendung von N-Methyl-Sphingosin als Zell-Wachstums-Inhibitor. Expired - Fee Related DE69019388T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30637889A 1989-02-03 1989-02-03
US39013589A 1989-08-07 1989-08-07

Publications (2)

Publication Number Publication Date
DE69019388D1 true DE69019388D1 (de) 1995-06-22
DE69019388T2 DE69019388T2 (de) 1996-01-04

Family

ID=26975128

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69019388T Expired - Fee Related DE69019388T2 (de) 1989-02-03 1990-02-02 Verwendung von N-Methyl-Sphingosin als Zell-Wachstums-Inhibitor.

Country Status (6)

Country Link
EP (1) EP0381514B1 (de)
JP (1) JP2976055B2 (de)
AT (1) ATE122560T1 (de)
CA (1) CA2007507C (de)
DE (1) DE69019388T2 (de)
DK (1) DK0381514T3 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5583160A (en) * 1989-02-03 1996-12-10 The Biomembrane Institute Methylsphingosine used to treat apoptosis
US5151360A (en) * 1990-12-31 1992-09-29 Biomembrane Institute Effect of n,n,n-trimethylsphingosine on protein kinase-c activity, melanoma cell growth in vitro, metastatic potential in vivo and human platelet aggregation
US5260288A (en) * 1992-04-03 1993-11-09 The Biomembrane Institute Method for inhibition of cell motility by sphingosine-1-phosphate and derivatives
IL121320A (en) 1997-02-23 2000-12-06 Ibr Ltd Extracts from cells or tissue of organisms which are capable of entering dormancy for inhibition of proliferation of target cells or tissue
US6107520A (en) * 1997-04-15 2000-08-22 The Board Of Trustees Of The University Of Illinois Spisulosine compounds
USRE38793E1 (en) 1997-04-15 2005-09-06 Rinehart Kenneth L Spisulosine compounds
US6800661B1 (en) 1997-04-15 2004-10-05 Board Of Trustees Of The University Of Illinois Spisulosine compounds
US6649362B2 (en) 1997-09-08 2003-11-18 Medvet Science Pty. Ltd. Screening method for an agent having an effect on a sphingosine kinase signaling pathway
AUPO900297A0 (en) * 1997-09-08 1997-10-02 Medvet Science Pty. Ltd. A method of modulating cellular activity
KR20020092958A (ko) * 2000-02-16 2002-12-12 파르마 마르.에스.에이. 항종양 활성을 가진 옥시- 및 아미노-치환된테트라하이드로푸릴 유도체
EP1195604A1 (de) * 2000-09-29 2002-04-10 Warner-Lambert Company Verfahren und Zusammensetzungen zum Screenen von Modulatoren von Lipidkinasen
WO2002060405A1 (en) * 2001-01-29 2002-08-08 Cosmoferm B.V. Veterinary dermatologic composition comprising a sphingoid base and/or a sphingoid base derivative
KR100457113B1 (ko) * 2001-12-27 2004-11-16 한국원자력연구소 세라마이드류 또는 그 유도체와 다이메틸스핑고신을 유효성분으로 포함하는 방사선민감도 증진제
KR100459484B1 (ko) * 2002-05-20 2004-12-03 한국원자력연구소 엔-아세틸 파이토스핑고신과 다이메틸 파이토스핑고신을유효 성분으로 포함하는 방사선 치료 민감제 조성물
EP1426053A1 (de) * 2002-12-03 2004-06-09 Fresenius Kabi Deutschland GmbH Verwendung von amphiphilen Lipiden zur Hemmung von Tumormetastasierung
ATE539741T1 (de) 2004-11-30 2012-01-15 Tno Sphingolipide bei der behandlung und prävention von hepatischer steatose
CA2812929C (en) * 2009-11-12 2015-02-03 Texas Tech University Compositions and methods for treating hyperproliferative disorders
JOP20190254A1 (ar) 2017-04-27 2019-10-27 Pharma Mar Sa مركبات مضادة للأورام

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816450A (en) * 1986-09-15 1989-03-28 Duke University Inhibition of protein kinase C by long-chain bases

Also Published As

Publication number Publication date
DK0381514T3 (da) 1995-09-04
JP2976055B2 (ja) 1999-11-10
EP0381514A3 (de) 1991-07-17
CA2007507A1 (en) 1990-08-03
DE69019388T2 (de) 1996-01-04
EP0381514B1 (de) 1995-05-17
EP0381514A2 (de) 1990-08-08
JPH03157336A (ja) 1991-07-05
CA2007507C (en) 1998-05-19
ATE122560T1 (de) 1995-06-15

Similar Documents

Publication Publication Date Title
DE69019388D1 (de) Verwendung von N-Methyl-Sphingosin als Zell-Wachstums-Inhibitor.
Wakitani et al. Repair of rabbit articular surfaces with allograft chondrocytes embedded in collagen gel
ES2115163T3 (es) Procedimiento para inhibir la proliferacion de celulas de musculos lisos y la restinosis.
DE122011100032I1 (de) Verwendung von n-substituierten pyridonen als tumornekrose-faktor alpha hemmer.
ES2175087T3 (es) Compuestos triciclicos utiles en el tratamiento de trastornos de proliferacion celular.
MX9803753A (es) Acidos alfa-iminohidroxamicos y -carboxilicos n-sustituidos ciclicos y heterociclicos.
DE69628556D1 (de) Tricyclische verbindungen als inhibitoren von farnesyl protein transferase
ZA907338B (en) Thienylcarboxylates of amino alcohols
CA2296036A1 (en) Dolastatin 15 derivatives
ATE107515T1 (de) Zusammensetzung zur behandlung von entzündung.
DE69229944D1 (de) Verwendung von N-Acylaminoalkoholen zur Herstellung eines Arzneimittels zur Behandlung von Mastzellerkrankungen
MX9701325A (es) Metodos para inhibir la mucositis ulcerativa.
ATE248592T1 (de) Verwendung von naaladase hemmern zur herstellung eines medikaments zur behandlung von bestimmten krankheiten
ATE199642T1 (de) Verwendung von 2-phenyl-3-aroylbenzothiophen derivaten zur herstellung eines medikaments zur hemmung des knorpelabbaus
FI101306B1 (fi) Menetelmä kudostyyppisen plasminogeeniaktivaattorin analogien, joissa on muokatut kasvutekijädomeenit, valmistamiseksi
DE69501359D1 (de) Verwendung von Phosphatdiestern zur Behandlung von Erkrankungen der Retina
ES2163528T3 (es) Una solucion acuosa para infusion, estable al almacenamiento, que contiene un inhibidor de trombina.
ATE213241T1 (de) Amidin- und isothioharnstoffderivate als inhibitoren der stickstoffoxid-synthase
ATE109006T1 (de) Pharmazeutische zusammensetzung bestimmt zur behandlung oder vorbeugung von retroviralen infektionen.
ATE123773T1 (de) 1,3,5-triazin-2,4,6-tris- alkylaminocarbonsäureaminoester, diese enthaltende biozide mittel sowie verfahren zu ihrer herstellung.
DE68916777D1 (de) Verwendung von TNF zur Herstellung eines Arzneimittels zur Behandlung von Psoriasis.
MX9701333A (es) Metodos para inhibir el daño neuronal.
Tyrrell Specific toxicity of aphidicolin to ultraviolet-irradiated excision proficient human skin fibroblasts
ATE240101T1 (de) Verwendung von 2-phenyl-3- aroylbenzothiophenderivaten zur herstellung eines medikaments zur knochen- und bruchheilung
ATE81971T1 (de) Synergistische kombination von decarboxylasehemmern und l-dopa-pellets.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee